Febuxostat is a promising inhibitor of xanthine oxidase that has yet to be studied as a secondary preventative measure for either uric acid nephrolithiasis or for hyperuricosuric calcium stone ...

The research, published in The BMJ, employs target trial emulation to provide insights into how these medications can simultaneously manage kidney stone recurrence and related comorbidities. "In a ...

1 2 In recent years, the prevalence of kidney stones has increased in parallel with the epidemics of obesity and metabolic syndrome, as well as cardiorenal disease. Since 1988, when the US Food and ...

You can create a release to package software, along with release notes and links to binary files, for other people to use. Learn more about releases in our docs.

"This class of drugs may be a useful addition to the current treatments for nephrolithiasis to simultaneously tackle the high burden of kidney stones and comorbidities, including gout," the authors ...

This project has not set up a SECURITY.md file yet.

“This class of drugs may be a useful addition to the current treatments for nephrolithiasis to simultaneously tackle the high burden of kidney stones and comorbidities, including gout,” the ...

Kidney stones are hard objects made from chemicals in your pee. They may be as tiny as a grain of salt or as big as a corn kernel. The stones can be brown or yellow, smooth or rough. They're a ...

There are four stages of passing a kidney stone: The stone forms, leaves the kidney, reaches the bladder and causes pressure, and finally, exits the body. They're common, with about 10% of people in ...